Correction to: Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment.

Watanabe, Akiko; Ishizuka, Tomoko; Yamada, Makiko; Igawa, Yoshiyuki; Shimizu, Takako; Ishizuka, Hitoshi

Watanabe, Akiko; Ishizuka, Tomoko; Yamada, Makiko; Igawa, Yoshiyuki; Shimizu, Takako; Ishizuka, Hitoshi.

Affiliation

Watanabe A; Quantitative Clinical Pharmacology Department, Daiichi, Sankyo Co., Ltd., Tokyo, Japan. watanabe.akiko.mi@daiichisankyo.co.jp.
Ishizuka T; Drug Metabolism and Pharmacokinetics Research, Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
Yamada M; Drug Metabolism and Pharmacokinetics Research, Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
Igawa Y; Quantitative Clinical Pharmacology Department, Daiichi, Sankyo Co., Ltd., Tokyo, Japan.
Shimizu T; Quantitative Clinical Pharmacology Department, Daiichi, Sankyo Co., Ltd., Tokyo, Japan.
Ishizuka H; Quantitative Clinical Pharmacology Department, Daiichi, Sankyo Co., Ltd., Tokyo, Japan.

Eur J Clin Pharmacol ; 78(1): 75, 2022 Jan.

Article in En | MEDLINE | ID: mdl-34494163

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies / Risk_factors_studies Language: En Journal: Eur J Clin Pharmacol Year: 2022 Document type: Article Affiliation country: Japan

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google